Anterogen.Co.,Ltd. (KOSDAQ:065660)

South Korea · Delayed Price · Currency is KRW

16,620

-280 (-1.66%)

Aug 12, 2026, 2:39 PM KST

-34.18% (1Y)

Market Cap	169.10B -31.6%
Revenue (ttm)	8.06B +15.1%
Net Income	-1.56B
EPS	-155.39
Shares Out	10.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,017
Open	16,980
Previous Close	16,900
Day's Range	16,430 - 16,990
52-Week Range	13,500 - 61,800
Beta	-0.12
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 065660

Full Company Profile

Financial Performance

In 2025, Anterogen.Co.,Ltd.'s revenue was 7.54 billion, an increase of 8.71% compared to the previous year's 6.93 billion. Losses were -1.37 billion, -40.08% less than in 2024.

Financial Statements